Arcturus Therapeutics Holdings Inc. (ARCT) Overview
Technical Analysis: ARCT has recently shown a bullish signal with its 50-day simple moving average crossing above the 200-day simple moving average, a pattern known as a "golden cross." This technical indicator often suggests a potential breakout in stock price.
Golden Cross Explained: The golden cross occurs when a stock's short-term moving average surpasses its long-term moving average, typically indicating a reversal from a downtrend to an upward trend. This pattern consists of three stages: a downtrend, the crossover of moving averages, and a subsequent price increase.
Recent Performance and Outlook
Stock Performance: Over the past four weeks, ARCT shares have increased by 38.3%, indicating strong upward momentum. The stock currently holds a #3 (Hold) rating on the Zacks Rank, suggesting it may be on the verge of further gains.
Earnings Expectations: Analysts have noted positive changes in ARCT's earnings estimates, with four upward revisions in the last 60 days and no downward changes. This trend supports the bullish outlook for the stock.
Investment Recommendations
Future Potential: Given the positive technical indicators and earnings revisions, investors are encouraged to monitor ARCT for potential gains in the near future.
Top Stock Picks: Zacks Investment Research has identified five stocks with a high probability of gaining over 100% in the coming months. Among these, a satellite-based communications firm is highlighted as a top pick, with expectations of significant revenue growth as the space industry is projected to become a trillion-dollar market by 2025.
Historical Context: The article references past successful picks, such as Hims & Hers Health, which saw a remarkable increase of 209%, indicating the potential for high returns among Zacks' recommendations.
Additional Resources
Stock Analysis Report: A free stock analysis report for Arcturus Therapeutics Holdings Inc. is available for those interested in further details.
Zacks Investment Research: The article emphasizes the importance of staying updated with the latest stock recommendations from Zacks Investment Research.
ARCT
$6.97+Infinity%1D
Analyst Views on ARCT
Wall Street analysts forecast ARCT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARCT is 31.29 USD with a low forecast of 9.00 USD and a high forecast of 72.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
Wall Street analysts forecast ARCT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARCT is 31.29 USD with a low forecast of 9.00 USD and a high forecast of 72.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
3 Hold
0 Sell
Moderate Buy
Current: 7.130
Low
9.00
Averages
31.29
High
72.00
Current: 7.130
Low
9.00
Averages
31.29
High
72.00
Citi
Yigal Nochomovitz
Neutral
downgrade
$12 -> $9
2025-11-13
Reason
Citi
Yigal Nochomovitz
Price Target
$12 -> $9
2025-11-13
downgrade
Neutral
Reason
Citi analyst Yigal Nochomovitz lowered the firm's price target on Arcturus Therapeutics to $9 from $12 and keeps a Neutral rating on the shares.
Piper Sandler
Piper Sandler
Overweight
downgrade
$140 -> $72
2025-11-11
Reason
Piper Sandler
Piper Sandler
Price Target
$140 -> $72
2025-11-11
downgrade
Overweight
Reason
Piper Sandler lowered the firm's price target on Arcturus Therapeutics to $72 from $140 and keeps an Overweight rating on the shares after the company reported Q3 earnings and provided a comprehensive update across their ARCT-032 CF and ARCT-810 OTC deficiency programs. The company discussed that they are on track to reach regulatory alignment on a pivotal ARCT-810 OTC deficiency program in the first half of 2026 where there will likely be two separate conversations for adult and pediatric populations. In regard to KOSTAIVE, management noted the U.S. BLA filing has been delayed indefinitely due to regulatory changes and uncertain U.S. commercial viability with reduction of additional expenses. Thus, Piper views the first half of 2026 as an important inflection point for the name with updates expected across both CF and OTC programs.
H.C. Wainwright
Buy
to
Neutral
downgrade
$60 -> $12
2025-10-24
Reason
H.C. Wainwright
Price Target
$60 -> $12
2025-10-24
downgrade
Buy
to
Neutral
Reason
H.C. Wainwright downgraded Arcturus Therapeutics to Neutral from Buy with a price target of $12, down from $60. The firm does not believe the company's cystic fibrosis program is worth progressing towards later stage clinical trials based on key opinion leader conversations regarding the interim Phase 2 ARCT-032 data. Arcturus would be better positioned to instead invest in early stage assets, the analyst tells investors in a research note.
Wells Fargo
Overweight -> NULL
downgrade
$42 -> $20
2025-10-23
Reason
Wells Fargo
Price Target
$42 -> $20
2025-10-23
downgrade
Overweight -> NULL
Reason
Wells Fargo lowered the firm's price target on Arcturus Therapeutics to $20 from $42 and keeps an Overweight rating on the shares. The firm Phase 2 data suggests establishing efficacy of inhaled mRNA may take more effort than expected. Wells does think mucus reduction data are intriguing, especially with anatomical consistency.
About ARCT
Arcturus Therapeutics Holdings Inc. is a commercial mRNA medicines and vaccines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. The Company with enabling technologies, including LUNAR lipid-mediated delivery, STARR mRNA technology (sa-mRNA) and mRNA drug substances along with drug product manufacturing. It has developed KOSTAIVE, a self-amplifying messenger RNA (sa-mRNA) COVID vaccine. The Company’s pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. The Company's versatile RNA therapeutics platforms can be applied to multiple types of nucleic acid medicines, including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
